Novartis announced recently that it has restarted radioligand therapy (RLT) production at two different sites.
Basel, Switzerland-based Novartis on June 30 said that it restarted production in “early June” at its Ivrea, Italy, and Millburn, New Jersey, sites, according to a news release. The company had halted production in May due to what it cited as potential quality issues in its manufacturing processes.
Radioligand therapy harnesses the power of radioactive atoms and applies it to advanced cancers to deliver radiation to target cells anywhere in the body with the aim of limiting damage to surrounding tissues through a targeted approach. Radioligands are also used in positron emission tomography.
The company also resumed delivery of doses to patients in a phased approach ahead of its expected six-week timeframe.
“The company has remediated the issues that led to the temporary, voluntary suspension of production in May,” …